Oncotarget

Research Papers:

High expression of Zinc-finger protein X-linked promotes tumor growth and predicts a poor outcome for stage II/III colorectal cancer patients

Xuebing Yan, Zezhi Shan, Leilei Yan, Qingchao Zhu, Liguo Liu, Bing Xu, Sihong Liu, Zhiming Jin and Yuping Gao _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:19680-19692. https://doi.org/10.18632/oncotarget.7547

Metrics: PDF 2241 views  |   HTML 2539 views  |   ?  


Abstract

Xuebing Yan1,*, Zezhi Shan1,*, Leilei Yan1, Qingchao Zhu1, Liguo Liu1, Bing Xu2, Sihong Liu2, Zhiming Jin1, Yuping Gao3

1Department of General Surgery, The Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, China

2Department of Medicine, Soochow University, Suzhou, Jiangsu Province, China

3Center for Reproductive Medicine, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

*These authors have contributed equally to this work

Correspondence to:

Zhiming Jin, e-mail: [email protected]

Yuping Gao, e-mail: [email protected]

Keywords: colorectal cancer, ZFX, tumor growth, prognosis, DUSP5

Received: September 15, 2015     Accepted: January 29, 2016     Published: February 21, 2016

ABSTRACT

Zinc-finger protein X-linked (ZFX) was recently identified as a novel oncoprotein in several human malignancies. In this study, we examined the correlation between ZFX expression and the clinical characteristics of stage II/III CRC patients, as well as the molecular mechanism by which ZFX apparently contributes to CRC tumor progression. Using immunohistochemistry, we detected expression of ZFX in CRC tissues collected from stage II/III patients and determined that its expression correlated with tumor differentiation and stage. Survival analysis indicated that patients with high ZFX expression had poorer overall and disease-free survival. ZFX knockdown in SW620 and SW480 CRC cells significantly inhibited cell proliferation and colony formation, enhanced apoptosis and induced cell cycle arrest. It also enhanced the sensitivity of CRC cells to 5-Fu. In a xenograft model, ZFX knockdown suppressed in vivo CRC tumor growth. Microarray analysis revealed the primary target of ZFX to be DUSP5. Whereas ZFX knockdown increased DUSP5 expression, DUSP5 knockdown rescued ZFX-mediated cell proliferation in ZFX knockdown cells. These findings demonstrate that ZFX promotes CRC progression by suppressing DUSP5 expression and suggest that ZFX is a novel prognostic biomarker and potentially useful therapeutic target in stage II/III CRC patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7547